Notice: This company has been marked as potentially delisted and may not be actively trading. NASDAQ:ARIA Ariad Pharmaceuticals (ARIA) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock Analysis About Ariad Pharmaceuticals Stock (NASDAQ:ARIA) 30 days 90 days 365 days Advanced Chart Get Ariad Pharmaceuticals alerts:Sign Up Key Stats Today's Range$23.99▼$23.9950-Day Range N/A52-Week Range$4.67▼$23.99VolumeN/AAverage Volume15.70 million shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewARIAD Pharmaceuticals, Inc. (ARIAD) is an oncology company. The Company is focused on transforming the lives of cancer patients with medicines. The Company's product pipeline includes Iclusig (ponatinib), brigatinib, AP32788 and ridaforolimus. The Company's Iclusig is a tyrosine kinase inhibitor (TKI) that is approved in the United States, the European Union, Australia, Switzerland, Israel and Canada for the treatment of adult patients with chronic myeloid leukemia (CML), and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Its Brigatinib is an investigational inhibitor of anaplastic lymphoma kinase (ALK). Its AP32788 is a TKI, which is designed as a targeted therapy for patients with non-small cell lung cancer (NSCLC) with specific mutations in two kinases, epidermal growth factor receptor (EGFR), or human epidermal growth factor receptor 2 (HER2). Its Ridaforolimus is an investigational inhibitor of the mammalian target of rapamycin (mTOR).Read More… Receive ARIA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ariad Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address ARIA Stock News HeadlinesResolution Therapeutics Announces £63.5 Million Series B Financing and Chair AppointmentOctober 3, 2024 | finance.yahoo.comSolu Therapeutics Strengthens Leadership Team with Appointment of Sergio Santillana, MD, as Chief Medical OfficerSeptember 10, 2024 | finance.yahoo.com$5,000 DOGE check?Elon Musk's DOGE agenda just took a very surprising turn... Earlier this week, reports emerged that a portion of the savings DOGE makes in Federal cuts could be funneled back to taxpayers. The media was quick to dub it a DOGE Dividend, with claims circulating that we could all receive a $5,000 check in the mail.February 22, 2025 | Altimetry (Ad)Affimed Appoints Shawn Leland As New CEOSeptember 3, 2024 | markets.businessinsider.comTerns Pharmaceuticals Finance Chief Vignola LeavingJuly 29, 2024 | marketwatch.comIDRx Appoints David P. Kerstein, M.D., as Chief Medical OfficerMarch 27, 2024 | finance.yahoo.comIDRx Strengthens Executive Team with Appointments of Tim Clackson, Ph.D., as CEO and Brad Dahms as CFO and CBOMarch 12, 2024 | finance.yahoo.comWhat Is Donanemab? Eli Lilly’s Alzheimer’s Drug Gets Delayed Decision From FDAMarch 8, 2024 | msn.comSee More Headlines ARIA Stock Analysis - Frequently Asked Questions How were Ariad Pharmaceuticals' earnings last quarter? Ariad Pharmaceuticals Inc (NASDAQ:ARIA) announced its earnings results on Thursday, July, 28th. The pharmaceutical company reported $0.59 earnings per share for the quarter, beating the consensus estimate of ($0.11) by $0.70. Ariad Pharmaceuticals's revenue for the quarter was up 133.0% compared to the same quarter last year. What other stocks do shareholders of Ariad Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Ariad Pharmaceuticals investors own include Synergy Pharmaceuticals (SGYP), Meta Platforms (META), Bristol-Myers Squibb (BMY), Twitter (TWTR), ACADIA Pharmaceuticals (ACAD), Ford Motor (F) and Gilead Sciences (GILD). Company Calendar Last Earnings7/28/2016Today2/22/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorN/A Industry N/A Sub-IndustryBiotechnology Current SymbolNASDAQ:ARIA CUSIP04033A10 CIK884731 Webwww.ariad.com Phone+1-617-4940400FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableOptionable BetaN/A Beginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report This page (NASDAQ:ARIA) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersThe Real Hillbilly ElegyThe mountains of Appalachia are incredible to behold. Spanning thousands of miles across Alabama, Kentucky...Porter & Company | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | Sponsored$5,000 DOGE check?Elon Musk's DOGE agenda just took a very surprising turn... Earlier this week, reports emerged that a porti...Altimetry | SponsoredThis Crypto Is Set to Explode in FebruaryIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredNvidia’s Next Big Move Comes on Feb. 26Nvidia isn't the only company that benefits greatly from these earnings calls. That's because a handful of ...Weiss Ratings | SponsoredCollect $7k per month from Tesla’s SECRET dividendThere's a little-known secret about Tesla that even seasoned investors don't know. Despite not paying a tra...Investors Alley | SponsoredMajor AI announcement for 2025BIG NEWS: “Market Wizard” Larry Benedict Releases a Whole New Way to Trade AI StocksBrownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ariad Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Ariad Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.